广泛与有限的基因小组以指导晚期固体瘤患者的治疗:一种随机对照试验
Olivier Trédan1,2, Damien Pouessel3, Nicolas Penel4
1Centre Léon Bérard, Lyon, France. olivier.tredan@lyon.unicancer.fr.
Nature medicine
|April 8, 2025
概括
较大的基因组显著增加了在晚期癌症患者的分子基础推疗法 (MBRTs) 的识别. 然而,这项研究没有发现临床结果的改善,强调需要进一步研究扩展MBRTs的好处.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 临床试验 临床试验
背景情况:
- 基因组分析对推进向癌症治疗至关重要.
- 更大的基因面板用于指导治疗决策的实用性需要进一步研究.
研究的目的:
- 为了比较综合基因小组 (Foundation OneCDX) 与有限小组 (CTL) 在确定晚期癌症患者的基于分子的推疗法 (MBRTs) 的疗效.
- 评估不同小组规模确定的MBRT对临床结果的影响.
主要方法:
- 一个多中心随机试验,涉及患有晚期/转移性固体癌症的患者.
- 用324基因面板 (F1CDX) 或87基因面板 (CTL) 来评估分子变化.
- 分子瘤委员会审查了研究结果,以推疗法 (MBRTs).
主要成果:
- 与有限的CTL小组 (36.9%) 相比,更大比例的患者接受了全面F1CDX小组的MBRT (51.6%),这是统计学上显著的差异 (14.8个百分点,P<0.001).
- 尽管MBRT识别增加了,但两组之间没有观察到无进展生存率,整体反应或安全性的显著差异.
- 在741名被查的患者中,有45.7%的患者可以获得质量检查的瘤样本.
结论:
- 综合性基因小组显著提高了在晚期癌症中基于分子的推疗法的识别.
- 扩展分子分析目前并未转化为改善该患者群体的临床结果.
- 需要进一步进行大规模研究,以确定扩展的MBRT在癌症治疗中的临床益处.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
997
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11.8K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K